Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients

被引:35
作者
Elbarbry, Fawzy A. [1 ]
Shoker, Ahmed S. [1 ]
机构
[1] Univ Saskatchewan, Royal Univ Hosp, Dept Med, Saskatoon, SK S7N 0W8, Canada
关键词
mycophenolic acid; therapeutic drug monitoring; drug analysis; HPLC; immunoassays; transplantation;
D O I
10.1016/j.clinbiochem.2007.03.006
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Introduction: Mycophenolic acid, the active metabolite of the prodrug mycophenolate mofetil, is widely used as an immunosuppressive agent in transplant patients for the prophylaxis of acute rejection. Recent prospective trials suggested the need for therapeutic drug monitoring, which raises the necessity to acquire accurate methods to measure MPA and its metabolites. Objective: Present an overview of the reasons to monitor MPA and its metabolites as well as a review of the currently available methods for their determination. Methods: Articles published from January 1992 to December 2006 were reviewed. Results: Most of the cited references use either chromatographic or immunoassay techniques. Basic information about biological samples used for the analysis, sample preparation, stationary phase, mobile phase, detection mode and validation data are discussed. Current information suggests the feasibility to set up method(s) to monitor MPA and its metabolites in most centers. (c) 2007 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:752 / 764
页数:13
相关论文
共 66 条
[1]   Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients [J].
Akhlaghi, F ;
Patel, CG ;
Zuniga, XP ;
Halilovic, D ;
Preis, IS ;
Gohh, RY .
THERAPEUTIC DRUG MONITORING, 2006, 28 (01) :95-101
[2]   Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry [J].
Annesley, TM ;
Clayton, LT .
CLINICAL CHEMISTRY, 2005, 51 (05) :872-877
[3]   Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mophetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection [J].
Aresta, A ;
Palmisano, F ;
Zambonin, CG ;
Schena, P ;
Grandaliano, G .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 810 (02) :197-202
[4]  
ASHIHARA Y, 2007, CLIN DIAGNOSIS MANAG, V1, P821
[5]   Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection [J].
Atcheson, B ;
Taylor, PJ ;
Mudge, DW ;
Johnson, DW ;
Pillans, PI ;
Tett, SE .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 799 (01) :157-163
[6]   Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia [J].
Atcheson, BA ;
Taylor, PJ ;
Kirkpatrick, CMJ ;
Duffull, SB ;
Mudge, DW ;
Pillans, PI ;
Johnson, DW ;
Tett, SE .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :284-286
[7]   An isocratic high performance liquid chromatographic method for quantification of mycophenolic acid and its glucuronide metabolite in human serum using liquid-liquid extraction: Application to human pharmacokinetic studies [J].
Bahrami, Gholamreza ;
Mohammadi, Bahareh .
CLINICA CHIMICA ACTA, 2006, 370 (1-2) :185-190
[8]   Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay [J].
Beal, JL ;
Jones, CE ;
Taylor, PJ ;
Tett, SE .
THERAPEUTIC DRUG MONITORING, 1998, 20 (06) :685-690
[9]   HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material [J].
Bolon, M ;
Jeanpierre, L ;
El Barkil, M ;
Chelbi, K ;
Sauviat, M ;
Boulieu, R .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 36 (03) :649-651
[10]   Determinants of mycophenolic acid levels after renal transplantation [J].
Borrows, R ;
Chusney, G ;
James, A ;
Stichbury, J ;
Van Tromp, J ;
Cairns, T ;
Griffith, M ;
Hakim, N ;
McLean, A ;
Palmer, A ;
Papalois, V ;
Taube, D .
THERAPEUTIC DRUG MONITORING, 2005, 27 (04) :442-450